United Therapeutics Corporation (UTHR) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Total Cash From Operating Activities Chart for United Therapeutics Corporation
United Therapeutics Corporation (UTHR) operating cash flow for FY2025 was USD 1.6B, a 17.6% change from FY2024. United Therapeutics Corporation's operating cash flow moved from USD -9.6M in 1998 to USD 1.6B in 2025 over 27 years. Operating cash flow compound annual growth rate: 5-year CAGR of 15.6%, 10-year CAGR of 15.1%, 20-year CAGR of 19.7%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $23.23B
- Implied Share Price
- $541.62
- Enterprise Value
- $18.22B
- Revenue (TTM)
- $3.15B
- EBITDA
- $1.50B
- Profit Margin
- 41.56%
- Trailing P/E
- 19.40
- Forward P/E
- 16.42
- Price/Book (MRQ)
- 3.33
- Price/Sales (TTM)
- 7.36
- EV/EBITDA
- 10.87
- EV/Revenue
- 5.78
- Dividend Yield
- —
- Book Value
- $149.97
- Free Cash Flow (FY2025)
- $1.04B
- Free Cash Flow Yield
- 4.48%
Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.